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A Fractured International Response to CRISPR-Enabled Gene
Editing of Agricultural Products
By CHRISTOPHER M. HOLMAN∗
ABSTRACT
IN 2015, SCIENCE MAGAZINE named CRISPR gene editing technology its
“Breakthrough of the Year,” and for good reason. CRISPR represents a
transformative advance in the ability of biotechnologists to edit genes and
genomes in both humans and nonhuman organisms. This article begins with a
discussion of recent advances in gene editing, including the development of
CRISPR and other sequence-specific nucleases (SSNs), and how this new
technology compares to other techniques for genetically modifying agricultural
plants such as selective breeding, induced random mutagenesis, and, more
recently, the use of recombinant technology to produce transgenic plants. It then
turns to the complex and dynamic regulatory framework for genetically modified
plants as it exists in the U.S., Europe, and elsewhere in the world, and how the
various regulatory regimes are responding to recent advances in biotechnology,
and in particular gene editing. The U.S. and many other nations appear to be
moving in the direction of less regulation for the products of gene editing
compared to transgenic crops produced using earlier technologies, while the
European Union (EU) on the other hand has indicated that it will subject the
products of gene editing to the same burdensome regulatory regime that has to
date constrained the development and utilization of GE crops in Europe.

IN 2015, SCIENCE MAGAZINE named CRISPR gene editing technology its “Breakthrough
of the Year,” and for good reason.1 CRISPR represents a transformative advance in the ability of
biotechnologists to edit genes and genomes in both humans and nonhuman organisms. The
implications of human gene editing are, of course, profound, but beyond the scope of this
Holman Report, which will instead focus on the application of gene editing to agriculture, and

∗
Christopher M. Holman, Professor of Law, University of Missouri-Kansas City School of Law; Senior Scholar,
Center for the Protection of Intellectual Property, Antonin Scalia Law School, George Mason University; and
Executive Editor, Biotechnology Law Report.
1

Science News Staff, And Science’s 2015 Breakthrough of the Year Is . . . , SCIENCE (Dec. 17, 2015), available at
https://www.sciencemag.org/news/2015/12/and-science-s-2015-breakthrough-year (last visited January 3, 2019).

PRE-PRINT VERSION (For print version see Christopher M. Holman, A Fractured International
Response to CRISPR-Enabled Gene Editing of Agricultural Products, 38 BIOTECHNOLOGY LAW
REPORT 3 (2019).)

more particularly the regulation of genetically engineered (GE) crops and other agricultural
plants produced using a sequence-specific gene editing technology such as CRISPR.
The article begins with a discussion of recent advances in gene editing, including the
development of CRISPR and other sequence-specific nucleases (SSNs), and how this new
technology compares to other techniques for genetically modifying agricultural plants such as
selective breeding, induced random mutagenesis, and, more recently, the use of recombinant
technology to produce transgenic plants. It then turns to the complex and dynamic regulatory
framework for genetically modified plants as it exists in the U.S., Europe, and elsewhere in the
world, and how the various regulatory regimes are responding to recent advances in
biotechnology, and in particular gene editing. As explained below, the U.S. and many other
nations appear to be moving in the direction of less regulation for the products of gene editing
compared to transgenic crops produced using earlier technologies, while the European Union
(EU) on the other hand has indicated that it will subject the products of gene editing to the same
burdensome regulatory regime that has to date constrained the development and utilization of GE
crops in Europe.

TECHNOLOGICAL ADVANCES IN THE GENETIC MODIFICATION OF PLANTS
In 2017, scientific advisory groups in the U.S. and Europe issued reports reviewing the
latest technical developments in agricultural biotechnology, including gene editing, entitled,
respectively, Preparing for Future Products of Biotechnology (the NAS Report) and Explanatory
Note: New Techniques in Agricultural Biotechnology (the EU Report).2 These reports proved

2

National Academies of Sciences, Engineering, and Medicine, Preparing for Future Products of Biotechnology
(National Academies Press 2017) (referred to hereafter as the NAS Report); Scientific Advice Mechanism: High
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PRE-PRINT VERSION (For print version see Christopher M. Holman, A Fractured International
Response to CRISPR-Enabled Gene Editing of Agricultural Products, 38 BIOTECHNOLOGY LAW
REPORT 3 (2019).)

useful in the preparation of this section of the article, which describes the advance of techniques
for improving agricultural genetics, from selective breeding techniques through the latest
developments in gene editing, and the interested reader is encouraged to consult them for further
insight into the technologies.
Humans have engaged in genetic engineering since the dawn of agriculture, around
13,000 years ago, selecting and retaining organisms suitable for agricultural use. Cultivated
crops and livestock possess dramatically altered traits and characteristics relative to any naturally
occurring source organism, and this was the case long before modern biotechnology arose in the
latter part of the twentieth century. Random mutations occur naturally, sometimes resulting in an
improvement (at least from the perspective of humans) in the organism, and by selective
breeding, these traits have been propagated and stacked in agricultural plants and animals.
Mutations can consist of changes at a single nucleotide position (point mutations), or sometimes
more complex changes, such as major rearrangements in the DNA (inversion, translocation) or
deletion of DNA fragments. Over time, selective breeding has provided huge benefits to
mankind, but it is subject to significant limitations, including the rarity of beneficial mutations
arising spontaneously without human intervention, the difficulty of identifying some beneficial
phenotypes, and the length of time it takes to proceed from one generation to the next through
conventional breeding of plants and animals.
Around 1920, a major breakthrough occurred when agriculturalists began inducing
mutagenesis in targeted organisms through the use of mutagens such as chemicals or radiation,
thereby greatly increasing the number of mutations and significantly improving the likelihood
that a desirable mutation will arise. Still, there are limits as to the extent to which certain
Innovation, New Techniques in Agricultural Biotechnology (Publications Office of the European Union 2017)
(referred to hereafter as the EU Report).
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characteristics can arise through mutagenesis even when induced. Furthermore, agriculturalists
were limited to traits that could be induced in the gene pools of sexually compatible organisms.
Because the mutation events are random, a large number of mutant plants must be generated and
screened to identify that rare useful mutation. Plants having desirable mutations will generally
also have large number of other uncharacterized mutations, some of which might be detrimental.
Agriculturalists use successive rounds of backcrossing with an elite variety in order to eliminate
unwanted traits, but due to limitations in conventional breeding, the final products are still likely
to carry uncharacterized and perhaps detrimental DNA alterations beyond the specific mutation
that provided the desired trait. To date, more than 3,200 different commercially available
varieties have been developed worldwide using induced mutagenesis.3 One well-known example
of a product of induced mutagenesis is the pink grapefruit.
The 1970s and 80s saw the developments of new techniques for genetically modifying
agricultural products, most notably recombinant DNA technology and techniques for introducing
foreign DNA into plant genomes. This allowed for the creation of transgenic plants, wherein a
genetic sequence of foreign origin is incorporated into the host plant’s genome. By removing the
limitation of sexual compatibility, the possibility for genetic enhancement through transgenics
greatly expanded the possibility of introducing valuable new traits into plants. Some of the most
notable and successful early efforts involved introducing bacterial genetic material into row
crops (like soybean, canola, corn, and cotton), conferring resistance to herbicides such as
glyphosate or the ability to express pesticides like Bacillus thuringiensis (BT) toxin. Other
notable examples of transgenic crops produced using conventional transgenic technology include

3

EU Report, supra note 2.
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virus-resistant squash and papaya, a non-browning apple, and a potato that is low in
polyacrylamide when cooked at high temperature.
In the early days of agricultural biotechnology, the primary means of introducing a
transgenic DNA construct into a host plant genome was through the use of Agrobacterium
tumefaciens, a bacterium that in its natural state transfers tumor-inducing DNA into a host plant
genome. Biotechnologists took advantage of the ability of Agrobacterium to incorporate foreign
DNA into a plant genome by engineering the bacterial DNA to eliminate undesirable tumorinducing genes and replacing them with genetic material intended for introduction into the host,
particularly genes encoding desired traits. Significantly, however, use of Agrobacteriummediated transformation generally results in the incorporation of at least some genetic material
of Agrobacterium origin into the plant genome, and because Agrobacterium is a plant pest, and
the U.S. Department of Agriculture (USDA) regulates plant pests, this artifact of the process has
historically triggered USDA regulatory oversight of most transgenic crops. Transgenic constructs
have also often contained foreign promoter sequences derived from a plant pest, like the widelyused cauliflower mosaic virus (CMV) promoter, which will likewise trigger USDA regulation.
Alternative methods of gene delivery to plants were also developed, including biolistics,
which involves coating metal microparticles with DNA and then forcibly shooting those particles
into target cells, sometimes resulting in incorporation of the DNA into the plant genome.4 As a
general matter, biolistics was less efficient in introducing foreign DNA than Agrobacteriummediated methods, but could be a useful alternative in some plants that proved refractory to the
use of Agrobacterium. Biolistic methods of introducing foreign DNA into a plant generally avoid
the introduction of plant pest DNA into the host plant, and therefore have generally not triggered
4

Biolistic gene delivery is sometimes referred to as “microprojectile bombardment,” and the device used to shoot the
microprojectiles as a “gene gun.”
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USDA regulation. This can be a significant advantage, and indeed might in some cases have
incentivized the use of biolistics rather than Agrobacterium.
Although transgenic technology greatly expanded the possibilities for genetic
enhancement of plants and animals, allowing the creation of traits like herbicide resistance and
endogenous pesticide expression that would have been difficult, if not impossible, to achieve
through conventional breeding techniques, the technology has its limitations. One in particular is
that the established methods for introducing DNA into the plant genome are random, and the
insertion event can occur anywhere in the genome, sometimes two or more times at different
locations. The resulting phenotype will vary dramatically depending on exactly where in the
genome the insertion occurs (a phenomenon known as position effect) because of the effect of
adjacent sequences and because of chromosomal structure at that particular location. The
insertion might result in insertional mutagenesis or affect the expression of endogenous genes, in
either case creating the potential for unintended effects on the phenotype. The insertion of more
than one exogenous genetic construct in the same genome can also cause problems, resulting for
example in gene silencing, so agricultural biotechnologists generally select for
commercialization a variety having a single copy of the transgenic construct.
Because of the variability in phenotype caused by the random nature of the insertion into
the plant host genome, agricultural technologists need to make a large number of transgenic
plants incorporating the desired DNA construct and screen for plants having the desired
phenotype, a laborious and time-consuming process, particularly if the phenotype can only be
observed by growing the plant from seed. Once a transgenic variety with the desired phenotype
has been identified, it will typically also have less-than-optimal genetic characteristics that have
come along for the ride. Repeated backcrossing with a non-transgenic variety having better
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overall genetics is generally necessary to arrive at a commercially desirable plant having the
desired transgenic trait in combination with an otherwise strong genetic background.
Successfully introducing multiple transgenic changes in a single plant genome is even more
difficult, which has limited the ability of agricultural technologists to introduce complex
phenotypic traits that require the expression of more than a single transgenic gene.
Recent advances in biotechnology have provided agricultural biotechnologists with new
tools and techniques that to a large extent overcome the shortcomings of conventional transgenic
technology and have opened the door to a new generation of genetically modified agricultural
products. Most notable are the sequence-specific nucleases, which allow for targeted
modification of plant genomes at a specific nucleic acid sequence, and in principle allow for
modification at a single and defined target site in the plant genome. Site-directed genome
modification also greatly facilitates the introduction of multiple, precisely defined genetic
changes in the genome of a plant without introducing the deleterious ancillary genetic
modifications typical of conventional breeding and earlier transgenic techniques.
The first sequence-specific nucleases to be applied to agriculture were the
meganucleases, followed by zinc finger nucleases (ZFNs) and transcription activator-like
effector nucleases (TALENs). The general utility of these nucleases was limited by the fact that
they all recognize the specific target DNA sequence through an interaction between a protein and
the target DNA sequence. Due to the inherent difficulty of reengineering a protein to specifically
recognize a different DNA sequence, these nucleases could not be readily modified to target a
specific DNA sequence of interest, and as a practical matter, their use was primarily limited to
modifications at a single genetic locus.
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This significant limitation was overcome by the more recent discovery and
characterization of the clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9
nuclease system, which recognizes its target DNA sequence through an RNA-DNA interaction.5
Because RNA is a nucleic acid, it is much more amenable to modifications that reengineer
CRIPSR to target any genomic DNA sequence of interests. The CRISPR-Cas9 nuclease system
has been shown to function in many organisms, including plants and animals, and is being used
to specifically introduce multiple genetic modifications into a single genome. The ability to
target integration to a specific location in the genome is advantageous because the location can
be targeted in such a way as to induce the desired level of expression of the genetic change while
minimizing undesired effects on the phenotype due to effects on neighboring genes.
Sequence-specific nucleases like CRISPR can be used to introduce a variety of types of
genetic modifications, including point mutations at a single nucleotide position, deletions of a
targeted stretch of sequence, or introduction of foreign DNA. Some products produced using
SSNs, such as single point mutations, deletions, or introduction of genetic material from a
sexually compatible species, will be indistinguishable from plants that could have arisen
spontaneously in nature through mutation or through induced mutagenesis and conventional
breeding. On the other hand, SSNs can be used to produce transgenic crops incorporating foreign
DNA from a non-sexually compatible organism, and in that sense, these products will be
indistinguishable from transgenics produced using established technologies. Transgenic plants
produced using gene editing will generally not incorporate foreign pest DNA, which is
significant in terms of regulation, particularly in the U.S. where, as discussed below, the USDA
has interpreted its authority to regulate transgenics as limited to those incorporating foreign pest
5

J.A. Doudna and E. Charpentier, The New Frontier of Genome Engineering with CRISPR-Cas9, 346 SCIENCE
12580 (2014).
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DNA, or resulting in some likelihood of the host plant becoming a pest. In some cases,
exogenous DNA will be incorporated into intermediate products of genome editing, but excised
from the final product, which is likely in some cases to greatly reduce the regulatory burden.
Much has been made of the potential for CRISPR technology to open the door for
genome editing of a wide variety of organisms, including humans, and the discovery of CRISPR
was no doubt a landmark achievement in the advance of biotechnology. But further advances in
gene editing seem inevitable. For example, non-Cas9 nucleases had been recently described for
CRISPR genome editing.6 Other gene editing approaches are emerging, including multiplex
automated genome engineering (MAGE), which permits multisite genome modifications through
hybridization of synthetic oligonucleotides during DNA replication.7
All of the techniques for genetically modifying organisms described above, including
conventional breeding techniques, have the potential for unintended consequences, and much of
the rationale behind regulating GE crops is a concern that some unintended effects could be
detrimental to the environment or to the health and safety of humans and animals consuming the
product. Unintended effects could result, for example, from disruption or alteration of the plant
genome that are ancillary to the modification conferring the desired trait characteristic. However,
there is every reason to believe that the products of the latest generation of agricultural
biotechnology techniques, particularly genome editing using SSNs, will be less likely to cause
unintended effects than either conventional breeding technology or first-generation transgenics.
Conventional breeding, particularly when used in conjunction with induced mutagenesis,
is prone to the introduction into the plant’s genome of multiple random mutations of generally
6

B. Zetsche et al., Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System, 163 CELL 759
(2015).
7
NAS Report, supra note 2, at 30; see, e.g., M.J. Lajoie et al., Genomically Recoded Organisms Expand Biological
Functions, 342 SCIENCE 357 (2013).
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unknown location and effect. Obviously deleterious mutations are often removed by
backcrossing with a sexually compatible plant lacking the desired mutation, but as a general
matter, conventional breeding techniques are expected to result in an improved product with
numerous uncharacterized mutations, any of which could potentially lead to unintended
deleterious consequences.
As described above, established recombinant techniques result in the random insertion of
the transgenic DNA into the plant genome, and multiple insertion events can also occur at
untargeted locations. Depending upon where these insertions occur, deleterious mutations or
alteration in expression patterns of the host genome are possible, potentially leading to
deleterious consequences. There is also the potential that the introduction of exogenous DNA
from a non-sexually compatible organism, such as Agrobacterium-derived genetic material or
regulatory sequences from plant pests, might have unintended consequences on the transgenic
plant. These potential unintended outcomes have been the focus of much of the regulatory
review of transgenic crops.
In contrast, because SSNs like CRISPR allow for the targeted insertion of DNA at a
known and characterized site in the host genome, it is possible to target the modification to a
region that is less likely to disrupt or alter the expression of endogenous genes of the host plant.
In principle, this should result in a lower likelihood of unintended deleterious effects in crops
produced using modern genome editing technology compared to earlier techniques for genetic
modification.
This is not to suggest that unintended effects will not occur with the use of CRISPR and
its kin. The employment of these technologies does not exclude “off-target” effects, where the
modification not only occurs at the targeted site but also at some other location in the genome
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with an identical or similar genetic sequence. But such off-target effects should be rare, and in
any event, less frequent than comparable off-target effects resulting from earlier technologies.
Also, with advances in whole genome sequencing and the availability of whole genome
sequences for targeted host plants, it should be feasible to identify and select for plants that have
only been modified at the intended target site.
It follows that the safety concerns associated with unintended consequences should
generally be less with the products of SSNs compared to earlier transgenics. The EU Report
concluded, for example, that while assessments of risk must always be made on a case-by-case
basis, genetically and phenotypically similar products derived using different techniques are
generally not expected to present significantly different risks. It follows that, as a general matter,
an organism whose genome has been edited to introduce a change that could have been achieved
through conventional breeding, such as a point mutation, deletion, or introduction of genetic
material from a sexually compatible organism, should not be viewed as posing a more significant
safety risk than the host of plants that have been developed over the last century using
conventional breeding techniques.
Changes introduced through genome editing that could have arisen out of conventional
breeding techniques will in many cases be difficult, if not impossible, to detect and identify.
With conventional transgenic crops, the presence of transgenic material can often be detected,
particularly if the sequence of the exogenous genetic material is known. For example, DNA
sequences originating in Agrobacterium have been determined and can thus be screened for.
However, in the absence of knowledge of a specific genetic modification that has been made,
detection of the change will be difficult, if not impossible. Using whole genome sequencing, it is
in principle possible to detect a change in the genome relative to some reference “unedited”
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genome. But in the case of a point mutation or other genetic modification that could have arisen
naturally or through conventional breeding, while detection of the change is possible, it will
generally be impossible to determine if the change was the result of genome editing or the
product of conventional breeding—that is, unless whoever is doing the analysis is provided with
prior information as to a specific modification that was produced using genome editing.
Numerous exciting and truly transformative applications of genome editing are currently
being pursued around the world. CRISPR is anticipated to open the door for creating improved
crops that will allow farmers to do more with less inputs, i.e., less water, less fertilizer, and less
pesticides, thereby providing not only substantial economic benefit but also benefits to food
security and the environment.8 Other anticipated products of genome editing will provide more
direct benefits to consumers, by providing more-nutritious, tastier, healthier, more-convenient,
and more-varied plant-based food.9

THE REGULATORY RESPONSE TO GENE EDITING IN AGRICULTURE
This section of the article looks at the regulatory regimes in the U.S., EU, Canada, and
Japan, and how they are responding to the use of gene editing on plants for agricultural purposes,
as well as a recent statement by the World Trade Organization (WTO) addressing the issue

NAS Report, supra note 2, at 40–44 and references cited therein.
Statement by the EU Group of Chief Scientific Advisors, A Scientific Perspective on the Regulatory Status of
Products Derived from Gene Editing and the Implications for the GMO Directive (Nov. 13, 2018) (referred to
hereafter as the Scientific Perspective), at 6 and references cited therein, available at
https://ec.europa.eu/info/sites/info/files/2018_11_gcsa_statement_gene_editing_2.pdf (last visited Jan. 3, 2019).

8
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The U.S.
Coordinated Framework for the Regulation of Biotechnology
In the 1970s and early 80s, the United States Congress considered legislation specifically
aimed at the regulation of products created through the use of biotechnology, but such
biotechnology-specific legislation was never enacted. Instead, President Reagan’s Office of
Science and Technology Policy (OSTP) stepped into the regulatory void in 1986 and published a
document, entitled Coordinated Framework for the Regulation of Biotechnology, pursuant to
which the primary responsibility for regulation of biotechnology products is shared by three
federal agencies: the U.S. Department of Agriculture, the U.S. Food and Drug Administration
(FDA), and the Environmental Protection Agency (EPA).10 The Coordinated Framework
essentially directs these agencies to regulate the products of biotechnology under nonbiotechnology-specific statutory provisions and agency practices that pre-date modern
recombinant biotechnology. The Coordinated Framework is intended to protect against risks to
human health and the environment that could potentially result from the development, release,
and consumption of genetically modified organisms (GMOs). At the time the Framework was
put in place, it was thought that an alternative, unitary statutory approach would be infeasible
given the very broad spectrum of products obtained through genetic engineering, with uses
cutting across the established regulatory jurisdictions of the different agencies. At the time the
Coordinated Framework was issued in 1986, it was understood that the regulatory requirements
of biotechnology were “expected to evolve in accord with the experiences of the industry and the

10

Office of Science and Technology Policy (OSTP), Coordinated Framework for Regulation of Biotechnology, 51
Fed. Reg. 23302 (June 26, 1986).
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agencies, and, thus, modifications may need to be made through administrative or legislative
actions.”11
The Coordinated Framework remains the foundation of the U.S. regulatory approach to
the products of agricultural and industrial biotechnology. In an attempt to provide further policy
guidance to the agencies, the Framework was updated in 1992. The 1992 Update to the
Coordinated Framework clarifies that GMO products should be regulated based on the
“characteristics of the organism, the target environment, and the type of application,” not on the
process by which the GMO was made.12 This focus on the product, as opposed to the process
used to make it, is significant, and stands in stark contrast to the regulatory approach adopted in
Europe, where the focus has been more on the process. Still, some regulated entities would argue
that despite the Framework’s focus on the characteristics of the product, in practice even in the
U.S., regulators have subjected products made using transgenic technology to much more
stringent and burdensome regulation than would be the case for comparable organisms produced
using conventional, pre-transgenic techniques. The 1992 Update to the Coordinated Framework
states that “[i]n order to ensure that limited federal oversight resources are applied where they
will accomplish the greatest net beneficial protection of public health and the environment,
oversight will be exercised only where the risk posed by the introduction is unreasonable.”
The following is a summary of the overlapping regulatory authority of the three primary
agencies pursuant to their current interpretation of the Coordinated Framework.

11

Id.
Office of Science and Technology Policy (OSTP), Exercise of Federal Oversight Within Scope of Statutory
Authority: Planned Introductions of Biotechnology Products Into the Environment, 57 Fed. Reg. 6753 (Feb. 27,
1992).
12
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USDA. Under the Plant Protection Act (PPA), the USDA is charged with promulgating
and enforcing regulations to protect U.S. crops from noxious weeds and plant pests, i.e., insects,
pathogens, and other organisms that harm plants. The agency has interpreted its role under the
Coordinated Framework as limited to the regulation of GE agricultural products that have been
altered by the introduction of genetic material derived from a plant pest, or when the
modification of the plant it is deemed likely to render the plant itself a plant pest, which it does
through regulations promulgated under the PPA and found at 7 C.F.R. part 340.13 The USDA’s
Animal and Plant Health Inspection Service (APHIS) enforces 7 C.F.R. part 340.
The PPA defines a “plant pest” such that it only applies to a plant that is parasitic, such as
mistletoe, and thus would not encompass the sorts of commercially relevant plants that have
been the subject of transgenic modification, so as a practical matter, USDA’s regulatory
jurisdiction in the area of GMOs has been confined to plants that have been modified by the
introduction of genetic material derived from a plant pest that is not itself a plant, such as a
bacterium or virus. Significantly, USDA has up until now chosen not to assert its authority to
regulate noxious weeds in the context of GMOs, although, as discussed below, in 2017, the
agency published proposed changes to 7 C.F.R. part 340 that would have done just that.
Under 7 C.F.R. part 340, a GE plant is treated as a regulated article if the donor organism,
recipient organism, vector, or vector agent used in engineering the organism belongs to one of
the taxa listed in 7 C.F.R. § 340.2 and is also considered a plant pest. APHIS regulates the
testing, release and commercialization of products falling within its jurisdiction, and can require
pre-market testing, risk analysis, and review for environmental impact under the National
Environmental Policy Act (NEPA). APHIS may issue a permit for the commercialization of a
13

Introduction of Organisms and Products Altered or Produced Through Genetic Engineering Which Are Plant Pests
or Which There Is Reason to Believe Are Plant Pests, 7 C.F.R. part 340.
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product that meets the regulatory definition. APHIS maintains post-market oversight in the form
of specific requirements on the introduction of the product and through its compliance and
inspection programs.
Historically, Agrobacterium-mediated transformation was the method of choice for
introducing foreign DNA into plants, and as an artifact of the process, the resulting GMOs
retained some Agrobacterium-derived DNA. Agrobacterium is a recognized plant pathogen, and
so the presence of its DNA in the products has triggered USDA regulation. The widespread use
of regulatory elements derived from plant pathogens, such as the cauliflower mosaic virus
(CMV) promoter, has likewise historically triggered USDA regulation of many GMO crops. In
the past, as a practical matter, the presence of plant pest DNA in engineered plant genomes has
resulted in the USDA having de facto regulatory authority over most of the first generation of
GMO crops.14
As mentioned earlier, however, there are alternative means for introducing foreign DNA
into a plant, such as biolistics, that do not result in the incorporation of plant pest genetic
material. USDA–APHIS has made the decision not to regulate GE plants engineered through
biolistics so long as the resulting crop contains no DNA sequence derived from a plant pest.
USDA regulation is often deemed burdensome, particularly by smaller or mid-sized innovators,
and this limitation on USDA regulatory jurisdiction has likely incentivized the development and
use of biolistics and other alternatives to Agrobacterium-mediated transformation.
Developers of GE plants can petition USDA for deregulation of a GE plant. If the USDA
decides to deregulate the plant, its release into the environment and commercialization will no

14

Kerry Grens, The Unregulation of Biotech Crops, THE SCIENTIST (Nov. 25, 2015), available at https://www.thescientist.com/news-analysis/the-unregulation-of-biotech-crops-34450 (last visited Jan. 3, 2019).
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longer be subject to USDA oversight. A list of granted and pending petitions for deregulation is
available on the USDA website.15
EPA. EPA is responsible for protecting human health and the environment. Under the
Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), EPA regulates field tests and the
commercial use of pesticides. Under section 408 of the Federal Food, Drug, and Cosmetic Act
(FDCA), EPA establishes the amount of pesticide chemical residues that may be present in food.
Pursuant to this authority, EPA provides regulatory oversight of plants that have been genetically
modified to express a pesticide, i.e., a biopesticide or plant-incorporated protectant (PIP). For
example, some of the most important early GMO crops were engineered to express the Bacillus
thuringiensis (Bt) toxin, a pesticide, which triggered EPA regulation. EPA regulates the pesticide
substance and related genetic material for human and environmental safety, including the safety
of dietary exposures to pesticide residues in human and animal food, e.g., allergenicity. If a crop
is genetically engineered to carry a gene for a Bt toxin, EPA requires the developer to verify that
the toxin is safe for the environment and conduct a food-safety analysis to ensure that the foreign
protein is not allergenic.16 A pesticide must thus meet two tests in order to be registered—the
benefit of using the pesticide must outweigh the risk, and any residues in food (including food
for animals) resulting from the use of the pesticide must meet the safety standard of section 408
of the FDCA.
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(last visited Jan. 3, 2019).
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If a GMO plant does not produce pesticide, EPA has taken the position that it does not
have regulatory authority. Although herbicide resistant plants are not directly regulated, the
herbicide itself is.
Under the Toxic Substances Control Act (TSCA) and regulations implementing that
statute, EPA also regulates biotechnology products that are new organisms not specifically
excluded by the statute (generally those regulated by other statutes). EPA has interpreted its
authority under the TSCA as limited to regulation of genetically modified microorganisms, not
plants or animals. If a microbe is intergeneric, and is manufactured or processed for commercial
production purposes, including research and development (R&D) for commercial purposes, for a
use that is not excluded under TSCA, nor otherwise exempt from reporting, it is under EPA’s
regulatory jurisdiction. EPA has not asserted authority to regulate genetically modified plants
that have not been engineered to produce a pesticide, although, as discussed later, it has been
suggested that the EPA could choose to interpret the TSCA more expansively and assert
regulatory oversight over any genetically modified organism released into the environment that
is not regulated by another agency.
FDA. FDA’s regulatory role under the Coordinated Framework arises primarily under the
FDCA, which charges FDA with the task of regulating the safety of products intended as food
for humans or feed for animals. Pursuant to this authority, FDA regulates genetically modified
products intended for use as food by humans or animals, including plants, animals, and
microorganisms. This encompasses a large percentage of genetically modified agricultural
products, both plant and animal. Once these genetically modified products enter the market, FDA
is authorized to regulate them for health and safety concerns, and if a genetic modification is
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found to result in an “adulterated” product, that product can be removed from the market and
sanctions imposed on the company responsible.17
Significantly, there is no mandatory pre-marketing approval requirement for food or feed
under the FDCA. FDA has, however, instituted a voluntary consultation process through which a
company developing a genetically modified food product can consult with the agency prior to
market entry to obtain FDA’s opinion as to whether the agency sees any safety concerns
associated with the contemplated product. These include the potential allergenicity and toxicity
of any newly-introduced proteins in food from the plant, whether any newly-introduced
substance in food from the plant requires premarket approval as a food additive, and whether
levels of endogenous toxicants and important nutrients or anti-nutrients have been changed in a
way that is relevant to food safety or nutrition. Although the consultation process is not legally
required, FDA reports that, to the best of its knowledge, all GE food crops intended for
marketing have been the subject of a consultation or other relevant pre-market processes prior to
marketing.
If genetic modification is deemed to create a food additive, then the food additive
provisions of section 409 of the FDCA would be triggered. Section 409 does require the premarket approval of any biomolecule introduced through genetic engineering that is deemed a
food additive.

The regulatory burden
Although numerous genetically modified products have successfully made their way
through the Coordinated Framework’s regulatory regime and entered the market, agricultural
17
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biotechnologists have complained that the process is unduly burdensome on innovators in terms
of cost, delay, and unpredictability. This creates a disincentive to the development of new GE
agricultural products, particularly for small or mid-sized companies and academic institutions
less able to deal with the complex regulatory framework than the large multinational
corporations that currently dominate agricultural biotechnology.
As discussed below, there are certain categories of GE crops that, under the current
interpretation of the Framework and the agencies’ jurisdictional reach, are not regulated by any
of the three agencies. At the other extreme, however, some GE crops fall under the jurisdiction
of all three agencies. Bt soybean produced using Agrobacterium-mediated transformation would
be one example, since the product is intended for use as food and has been engineered to
incorporate plant pest DNA and express a pesticide.
Agricultural innovators have reported that with respect to some GE crops, there has been
uncertainty as to which agency or agencies will assert jurisdiction. For a product that is subject to
regulation by more than one agency, the regulated innovator must deal with multiple agencies,
whose requirements might be different or even inconsistent, and under circumstances in which it
is unclear whether any agency has primary authority. Without an identified lead agency, a
regulated entity has trouble knowing which to approach for initial consultation.
It can take a great deal of time for an innovator to achieve regulatory approval for a new
GE crop. For example, an article in The Scientist describes how it took more than a decade for a
company called Okanagan Specialty Fruits to achieved deregulated status from the USDA for its
non-browning “Arctic” apple, which relies on the use of cauliflower mosaic virus promoter
delivered via Agrobacterium-mediated transformation to silence an enzyme that causes
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browning.18 This use of plant pest–derived DNA triggered USDA regulation of field trials and
marketing of the product. Field trials were first planted and 2003 and 2005, the company
submitted documentation to USDA 2010 requesting deregulation, and it took another five years
of review and public comment before the agency announced its decision deregulating the apple.
In retrospect, the company’s president expressed frustration at how long and costly the process
for achieving USDA deregulation was, particularly given the relatively minor genetic change
that had been made compared to other approved biotech crops. “For a small, grower-led
company like ours (our team had less than five full time employees when we submitted the
USDA petition), it was a monumental challenge to go through such a lengthy, costly process to
achieve deregulation.”19
Many would argue that the regulatory delays and expenses on the use of recombinant
DNA technology is unduly burdensome and continues to be disproportionate to its risk, and that
the opportunity costs of regulatory delays and expenses are formidable. According to a survey
completed 2011, the cost of discovery, development, and authorization of a new plant
biotechnology trait introduced between 2008 and 2012 was $136 million.20 On average, about 26
percent of those costs ($35.1 million) were incurred as part of the regulatory testing and
registration process.21 In 2011, the USDA instituted the “Am I Regulated?” process to help seed
innovators determine if their products need to go through the full-blown regulatory process, by
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providing the opportunity for an initial screening to determine if there is sufficient potential for
problems to warrant a closer look.22

Gaps within the Coordinated Framework
While there is redundancy under the Framework, conversely, there are significant gaps in
coverage whereby some GE products apparently fall outside the regulatory jurisdiction of any of
the agencies. For example, none of the three federal agencies would appear to have jurisdiction
over a GE plant that is not a plant pest or noxious weed, does not contain plant pest DNA or
DNA encoding a pesticide, and is not intended as food for humans or animals or to produce a
drug. Examples could include ornamental, silvicultural, and turfgrass crops, or crops used to
produce a non-food, non-drug product, like a chemical, fuel, or structural material.
USDA’s jurisdictional limitations were identified as far back as 2000 in a National
Research Council report and have been discussed in the literature.23 With the development of
new methods for introducing foreign DNA into plants and regulating foreign gene expression
that does not involve the use of plant pest DNA, USDA is increasingly coming to the conclusion
that it does not have regulatory jurisdiction over recently developed GE plants.
One interesting case that caught the attention of the mainstream media involved a do-ityourself biotechnology (DIYbio) project that resulted in a genetically engineered bioluminescent
plant dubbed the “Glowing Plant.”24 The process used did not result in the introduction of plant
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pest DNA into the product, and it was not intended for use as food or feed, so under the
prevailing interpretation of the Coordinated Framework, none of the three agencies had a
jurisdictional hook to regulate the public release of the GE plant—which not surprisingly
resulted in perceived safety concerns.25 However, the Glowing Plant project was conceived as
the starting point for future modifications by DIY biotechnologists, and its developers
encouraged others to further modify the plant’s genome using a kit that included Agrobacteriumbased transformation materials and protocols which, if used, would result in the introduction of
plant pest DNA into the resulting product, thereby triggering USDA regulation.
While the Glowing Plant project captured the attention of the popular press, a more
commercially significant example of a regulatory blind spot arose in 2011 when the USDA was
asked to review the regulatory status of a genetically engineered grass species transformed using
biolistics. The agency concluded that it did not have regulatory authority over the product since
the engineering did not incorporate plant pest DNA into the grass, and the engineered grass itself
was not deemed likely to be a plant pest.26 And because the grass is not intended for use as food
or feed, and does not contain a pesticide, under current interpretation of the Coordinated
Framework it does not fall under the regulatory authority of FDA or EPA. According to the NAS
Report, between that decision in 2011 and December 2016, more than 40 GE plant products were
submitted to USDA–APHIS for a determination as to whether they fell within the regulatory
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purview of the agency, and most of them were reportedly determined to be outside the scope of
the agency’s authority to regulate plant pests.27

Recent initiatives to reform and modernize the Coordinated Framework
In July 2015, the Obama administration released a memorandum charging the FDA,
EPA, and USDA with the task of Modernizing the Regulatory System for Biotechnology
Products (the 2015 EOP memorandum). 28 The memorandum notes that while

the current regulatory system for the products of biotechnology effectively protects health
and the environment, in some cases, unnecessary costs and burdens associated with
uncertainty about agency jurisdiction, lack of predictability of timeframes for review, and
other processes have arisen. These costs and burdens have limited the ability of small and
mid-sized companies to navigate the regulatory process and of the public to understand
easily how the safety of these products is assured.

The memorandum found it to be imperative that U.S. regulatory system be reformed in a
manner that would reduce regulatory burdens on innovators in order to avoid “unjustifiably
inhibiting innovation, stigmatizing new technologies, or creating trade barriers,” by improving
transparency, predictability, and efficiency of the regulation and improving the coordination
among the three agencies.
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The 2015 EOP memorandum provides for the creation of a Biotechnology Working
Group comprising representatives from the Executive Office of the President (EOP) and the
three agencies, and charges the working group with the tasks of: (1) updating the Coordinated
Framework to clarify the current roles and responsibilities of the agencies that regulate the
products of biotechnology; (2) developing a long-term strategy to ensure that the federal
regulatory system is equipped to assess efficiently the risks, if any, associated with future
products of biotechnology while supporting innovation, protecting health and the environment,
maintaining public confidence in the regulatory process, increasing transparency and
predictability, and reducing unnecessary costs and burdens; and (3) in order to inform future
policymaking, to commission an external, independent analysis of the future landscape of
biotechnology products that will identify potential new risks and frameworks for risk assessment
and areas in which the risks or lack of risks relating to the products of biotechnology are well
understood.
In response to the third charge, the working group commissioned a report from National
Academies of Sciences, Engineering, and Medicine aimed at providing a better understanding of
the landscape of future products of biotechnology, which resulted in in the 2017 NAS Report,
which concludes:

While the current regulatory system for the products of biotechnology effectively
protects health and the environment, in some cases unnecessary costs and burdens
associated with uncertainty about agency jurisdiction, lack of predictability of
timeframes for review, and other processes have arisen. These costs and burdens
have limited the ability of technology developers, particularly those in small and
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mid-sized companies and in academic research institutions, to navigate the
regulatory process and have limited the ability of the public to understand easily
how the safety of these products is assured. Accordingly, the costs and burdens
have the potential to hamper economic growth, innovation, and competitiveness.29

In response to the first two charges, the EOP in 2016 published a National Strategy for
Modernizing the Regulatory System for Biotechnology Products, which includes a number of
commitments from the three agencies for actions and reforms.30
In January 2017, the EOP followed up with an update to the Coordinated Framework
entitled Modernizing the Regulatory System for Biotechnology Products: An Update to the
Coordinated Framework for the Regulation of Biotechnology, the first update to the Coordinated
Framework in more than 20 years.31 Significantly, this Update to the Coordinated Framework
does not provide for any actual updates or changes to the framework, merely providing
clarification as to how the Coordinated Framework has and presumably will continue to be
applied, nor does it specifically address gene editing.

The agencies’ response to gene editing
This section of the article discusses how the three agencies have responded to the arrival
of gene editing of plants for agricultural purposes.
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USDA. Because the new gene editing techniques do not result in the introduction of plant
pest DNA into the host, as a general matter, these plants will apparently not be subject to USDA
regulation, at least under the USDA’s current view of its own regulatory authority. As of 2016,
USDA–APHIS had considered several cases of crops engineered with genome-editing
technology that caused directed insertions or deletions of one to several bases and determined
that the plants are not subject to USDA regulation. Even in cases where plant pest genetic
material is used in the developmental stages of a genetically modified product, it will often be
possible to remove those from the final product. In these situations, USDA has not required premarket testing, has not reported a risk finding, nor has it undertaken a NEPA analysis. USDA–
APHIS responses to letters of inquiry regarding the regulatory status of proposed GE plants often
contain language with recommended actions for developers to ensure that plant pest genetic
sequences will not be present in the final product. Genome-edited crops have, however, been
found subject to USDA regulation if the final product retains DNA that originated in a plant pest.
One example of a gene-edited agricultural product that was assessed by USDA and found
to be outside its regulatory purview is a mushroom engineered to resist browning through gene
editing that essentially turned off a gene in mushrooms that produces an enzyme that causes
browning, the equivalent of a naturally occurring “null” mutation.32 Similarly, in 2014 a research
team from Iowa State asked USDA whether its disease-resistant rice, produced by gene editing
using TALENs technology, would be regulated. Although Agrobacterium-based transformation
was used as an intermediate step, the final product did not contain any inserted genetic material,
and the agency determined that in the absence of any inserted genetic material and no reason to
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believe that the rice would constitute a plant past, the plant is not subject to USDA regulation.33
USDA warned the Iowa State researchers that GE rice plants from this transformation that retain
inserted genetic material would be considered regulated under 7 C.F.R. part 340.
In January 2017, USDA–APHIS published a proposed rule (the “2017 Proposal”) for
comment that specifically addressed the products of gene editing and that would, if implemented,
have significantly changed the manner in which the USDA regulates GE plants.34 In November
2017, after considering comments it received from the public, the agency withdrew the proposed
rule.35 Nevertheless, it is worth reviewing the 2017 Proposal because even though it was
withdrawn, it seems likely that the USDA will ultimately move in the direction charted by the
proposal, and in fact the agency issued a statement in 2018 adopting certain aspects of the 2017
Proposal, as discussed below.
The 2017 Proposal states that the agency’s 30 years of experience regulating GE crops
has provided evidence that most genetic engineering techniques, even those that use a plant pest
as a vector, vector agent, or donor, do not result in a GE organism that presents a plant pest risk.
On the other hand, the agency notes that the use of new techniques for genetically modifying
plants is increasingly resulting in the release of plants that could potentially pose a threat to
agriculture, but which are not subject to USDA’s regulatory jurisdiction under its current
regulations.
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The 2017 proposal would address the issues identified above by expanding the scope of
USDA regulation under 7 C.F.R. part 340 to encompass GE plants that could potentially
constitute noxious weeds. As mentioned above, the PPA provides for regulation of noxious
weeds, but up until now, USDA’s regulations promulgated under the statute have been limited to
GE plants that either incorporate plant pest DNA or which could themselves be considered a
plant pest (which as a practical matter never happens); GE plants have to date not been regulated
as potentially noxious weeds. USDA states that its proposal to expand its regulatory authority to
encompass potentially noxious weeds is driven primarily by two consequences of recent
advances in agricultural biotechnology, particularly the development of non-Agrobacteriumbased techniques for introducing foreign DNA into a plant’s genome and sequence-specific gene
editing.
First, as a practical matter, GE crops have until recently generally been subject to USDA
regulation owing to the presence of genetic material from Agrobacterium or another plant pest,
but with the more modern techniques like biolistics and gene editing that do not result in the
incorporation of plant pest–derived DNA the USDA has lost this jurisdictional hook. Secondly,
the nature of GE plants is changing with the advances in technology, such that it appears more
likely that the GE products of the future could pose a threat as noxious weeds. The original
targets for genetic modification were crops like corn, soybean, and canola, plants that are not
plant pests and are not likely to be turned into plant pests by the modifications that were being
made. But today genetic modifications are increasingly being introduced into plants that are
more weed-like in character, such as switchgrass for biofuel production, thereby increasing the
likelihood that a genetic modification might result in a plant with a greater tendency towards
becoming a weed.
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On the other hand, the agency proposes that in the future, GE plants that incorporate plant
pest DNA, such as Agrobacterium-transformed plants, will be scrutinized more for their potential
to be noxious weeds, rather than focusing so much on the plant pest DNA that has been
introduced, given the generally safe track record of GE plants produced using Agrobacteriummediated transformation and other established techniques that involve the use of plant pest DNA.
Under the 2017 Proposal, APHIS would begin its regulatory review of a new GE variety
by evaluating whether the plant, in its unmodified state, has weedy characteristics, i.e., a plant
biologically capable of causing “notable physical injury or damage” to crops. This would serve
as the baseline against which to evaluate the genotype of the GE plant. In evaluating the GE
plant, APHIS would assess the likelihood that the modifications made to the genome of the plant
would alter its ability to cause notable physical harm or injury.
For GE plants that APHIS determines to be weedy prior to genetic modification, APHIS
would endeavor to determine whether the plant’s weediness has been enhanced to an extent that
it has been engineered into a noxious weed. For GE plants that APHIS determines not to possess
weedy traits prior to modification, APHIS would endeavor to determine whether weediness had
been introduced into the organism through genetic engineering. Finally, in the event that a
Federal noxious weed (a subcategory of noxious weeds) is genetically engineered (something
that has not occurred to date), APHIS would endeavor to determine whether the GE plant is still
a noxious weed and warrants continued regulation.
If APHIS determines that the GE plant is a noxious weed, it would endeavor to gauge the
direct or indirect injury or damage it could cause to crops, livestock, poultry, or other interests of
agriculture, irrigation, navigation, the natural resources of the United States, the public health, or
the environment. APHIS would no longer consider GE organisms to be regulated articles solely
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because of the donor, vector, or vector agent used in genetic engineering, thereby focusing its
resources on those GE organisms that may present a plant pest and/or noxious weed risk.
Of particular relevance to gene editing, the 2017 Proposal clarifies that USDA regulation
under 7 C.F.R. part 340 has and will continue to only apply to an organism that is a “GE
organism,” defined as an organism developed using “genetic engineering.” The proposal would
define “genetic engineering” as “techniques that use recombinant or synthetic nucleic acids with
the intent to create or alter a genome.” The definition explicitly excludes traditional breeding
techniques and chemical- or radiation-based mutagenesis, which the agency has never considered
to constitute genetic engineering. Note that this only applies to regulation under 7 C.F.R. part
340, and does not restrict other potential bases for USDA regulation.
APHIS would also exclude from its definition of GE organism those that are created
using techniques that fall within the scope of genetic engineering, but that could otherwise have
been produced using traditional breeding techniques or chemical- or radiation-based
mutagenesis. The USDA has concluded that such organisms are essentially identical, despite the
method of creation, because while there may be small genetic differences, those differences are
not phenotypically observable and these types of changes occur naturally in all organisms.
APHIS would also exclude “null segregants,” that is, the progeny of a GE organism where the
only genetic modification was the insertion of donor nucleic acid into the recipient’s genome, but
the donor nucleic acid is not passed to the recipient organism’s progeny and the donor nucleic
acid has not altered the DNA sequence of the progeny.
To summarize, for purposes of the revised regulations, an organism would not be
considered a GE organism if:
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(1) The genetic modification to the organism is solely a deletion of any size or a single
base pair substitution which could otherwise be obtained through the use of chemical- or
radiation-based mutagenesis;
(2) The genetic modification to the organism is introducing only naturally occurring
nucleic acid sequences from a sexually compatible relative that could otherwise cross
with the recipient organism and produce viable progeny through traditional breeding
(including, but not limited to, marker-assisted breeding, as well as tissue culture and
protoplast, cell, or embryo fusion); or
(3) The organism is a “null segregant.”

APHIS would exclude the first two types of organisms from the definition of GE
organism because the organisms could have been produced from techniques that have never
triggered USDA regulation under 7 C.F.R. part 340, and that would continue to be excluded
from the definition of genetic engineering under the proposed revision to the regulations. The
USDA points out that chemical- and radiation-based mutagenesis creates thousands of mutations
in a single organism, and most of a plant breeders’ subsequent efforts involve eliminating
unwanted mutations by repeated crosses and selection, each of which can take months to years to
complete. Conversely, using genetic engineering, single base pair substitutions, as well as
deletions of differing sizes, can be precisely administered very quickly, avoiding this lengthy
process of eliminating unwanted mutations. The resulting organism, however, remains identical
to one that could otherwise have been developed using chemical- or radiation-based
mutagenesis.
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Similarly, traditional breeding techniques may require many generations of crossing to
introduce a naturally occurring trait. For example, it can take decades to introduce a diseaseresistant trait to apples through traditional breeding techniques. However, genetic engineering
can introduce the same trait in a fraction of the time while maintaining all other cultivar
characteristics of the apple.
Another rationale behind the first two exclusions is USDA’s conclusion that GE plants as
a class pose no greater plant pest or noxious weed risk than their counterparts developed through
traditional breeding techniques or chemical- or radiation-based mutagenesis. Moreover, the
agency deems it both impracticable and unnecessary to regulate plants created through traditional
breeding techniques or chemical- or radiation-based mutagenesis for plant pest or noxious weed
risk.
The USDA points out that traditional breeding techniques, in the form of deliberate
selection and breeding of those plants with desirable phenotypes, have been used since the
advent of sedentary agriculture, and nearly every domesticated crop has, at one point, been
subject to traditional breeding techniques. Chemical- and radiation-based mutagenesis, in turn,
have been used for nearly a century in the development of thousands of commodities, including
such commercial products as ruby red grapefruit and many commercial varieties of wheat and
rice. If APHIS were to regulate organisms developed through traditional breeding techniques or
chemical- or radiation-based mutagenesis, that would entail the regulation, at least provisionally,
of almost every commercially available human or animal food crop, which the agency would
find impracticable.
Furthermore, USDA states that the regulation of such organisms would fail to take into
adequate consideration that phenotypic traits that could increase the plant pest or noxious weed

PRE-PRINT VERSION (For print version see Christopher M. Holman, A Fractured International
Response to CRISPR-Enabled Gene Editing of Agricultural Products, 38 BIOTECHNOLOGY LAW
REPORT 3 (2019).)

risk posed by a plant tend to also adversely impact its vitality, uniformity, or commercial
viability. For example, a mutation caused by chemical- or radiation-based mutagenesis could
render a plant more susceptible to certain viroids or pathogens and able to transfer this increased
susceptibility to sexually compatible relatives, and thus increase the plant pest risk associated
with the plant. However, it would also directly adversely affect the plant’s vitality. For these
reasons, farmers and developers have long bred out unwanted phenotypic traits that arise as the
result of traditional breeding techniques and/or chemical- or radiation-based mutagenesis, and
planted and/or commercialized the most phenotypically desirable plant produced using such
techniques.
Regarding the proposed exclusion for null segregants, i.e., the progeny of GE organisms
where the only genetic modification was the insertion of donor nucleic acid into the recipient’s
genome, but the inserted donor nucleic acid is not passed to the recipient organism’s progeny and
has not altered the DNA sequence of the recipient organism’s progeny, the 2017 Proposal notes
that traits can sometimes be introduced by genetic engineering into breeding lines to simplify
breeding without altering the DNA sequence of progeny, and that such traits can be eliminated
with a simple cross and are no longer present in the final organism. An example of the use of
such techniques to facilitate traditional breeding would be the introduction of certain genes into
trees solely to reduce the time to flowering, thereby speeding up a tree-breeding program. In this
example, the progeny do not contain the early flowering gene and their DNA sequence has not
been altered by the early flowering gene. Because the DNA of the progeny is no different from
the DNA of the recipient organism prior to the use of genetic engineering, APHIS does not
consider the progeny to be GE organisms for purposes of the proposed regulations.
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As noted above, in November 2017, after considering comments it received from the
public, the agency withdrew the proposed rule.36 Perhaps the change in presidential
administrations had something to do with the decision. In any event, in March 2018, USDA
issued a statement adopting some aspects of the 2017 Proposal by announcing that the agency
will not assert regulatory authority over genetically altered plants so long as they could have
been developed in the alternative through traditional breeding methods, such as cross-breeding or
selecting for desirable properties.37 The agency noted that genome editing allows breeders to
introduce new traits more precisely, and at a faster rate. “With this approach, USDA seeks to
allow innovation when there is no risk present,” U.S. Secretary of Agriculture Sonny Perdue said
in the statement. “Plant breeding innovation holds enormous promise for helping protect crops
against drought and diseases while increasing nutritional value and eliminating allergens.” The
statement does not say anything about gene editing that results in incorporation of foreign DNA
into the genome.
EPA. As explained above, under FIFRA EPA regulates GE crops that have been
modified to express a pesticide, which EPA refers to as a plant-incorporated protectant (PIP).
FIFRA specifically exempts “pesticidal substances produced through conventional breeding of
sexually compatible plants,” and EPA has exempted from FIFRA requirements PIPs that occur
naturally in the plant or are moved through conventional plant breeding.38 This raises the
question of whether EPA would assert regulatory authority in a case where a pesticidal activity,
such as disease resistance, has been introduced through gene editing, particularly if the
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modification of the genome could have been achieved in the alternative using conventional
breeding and/or induced mutagensis. As noted above, USDA has promoted this approach, and it
seems reasonable that the EPA could follow that same path and decide not to regulate such
products of gene editing even though the result is a new pesticidal activity. To this author’s
knowledge, EPA has not issued a statement directly addressing this question. However, an EPA
PowerPoint presentation dated May 2018 and posted online does state: (1) the FIFRA exemption
for pesticidal activity introduced through conventional breeding predates site-specific gene
editing technologies like CRISPR; (2) “knockouts could still be considered as PIPs depending on
claims made and intent of product (e.g., disease resistance)”; and (3) “PIPs would need to be
specifically exempted from FIFRA through rule-making in order to bypass regulation.”39
The EOP’s 2016 National Strategy for Modernizing the Regulatory System for
Biotechnology states that the EPA has committed to clarifying its approach to pesticidal products
derived from genome editing techniques in a manner “consistent with the principles for the
regulation of biotechnology products articulated in the Coordinated Framework and the goals
and objectives of the July 2015 EOP memorandum.”
Under its current interpretation of its own regulatory jurisdiction EPA would not have a
basis for asserting regulatory authority over gene-edited plants that have not been engineered to
express a pesticide. However, there has reportedly been internal pressure at EPA to expand the
agency’s regulatory reach under the TSCA.40 The NAS Report states that the Coordinated
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Framework, as drafted in 1986, described the TSCA as a “back-stop” authority that could be
applied to any biotechnology organism that did not fall under the jurisdiction of any other statute
or agency.41 However, I must point out that when this author read the Coordinated Framework as
drafted in 1986, I did not see reference to the TSCA as a back-stop. The NAS Report also states
that in 2001 the Executive Office of the President’s Office of Science and Technology Policy
and Council on Environmental Quality’s biotechnology case studies concluded that EPA has
authority under the TSCA over a variety of biotechnology organisms, including plants and
animals, although this author was unable to access any document that would confirm this.42 The
NAS Report goes on to note that to date, EPA does not appear to have exercised its authority
under TSCA in this way, and questions whether this regulatory restraint is due to insufficient
resources or to the agency’s interpretation of its own authority under the statute. The Report
states that it “would be helpful if the federal government would make a policy determination as
to whether EPA will serve this gap-filling role.”
FDA. In January 2017, the FDA published a Request for Comments on questions related
to use of genome editing in new plant varieties used for food for humans and animals.43 In
October 2018, FDA issued its Plant and Animal Biotechnology Innovation Action Plan, which
provides an “overview of the key priorities the FDA will pursue to support innovation in plant
and animal biotechnology and to advance the agency’s public health mission.” 44 The Plan
summarizes FDA’s efforts to respond to advances in biotechnology, and particularly points to

41

NAS Report, supra note 2, at 95.
Id.
43
FDA, Genome Editing in New Plant Varieties Used for Foods; Request for Comments, 82 Fed. Reg. 6564 (Jan. 19,
2017).
42

44
FDA, Plant and Animal Biotechnology Innovation Action Plan (Oct. 2018), available at
https://www.fda.gov/downloads/Safety/Biotechnology/UCM624517.pdf (last visited Jan. 3, 2019) (“Human medical
products such as human drugs, biologics, and medical devices are not within the scope of activities envisioned under
this Action Plan.”).

PRE-PRINT VERSION (For print version see Christopher M. Holman, A Fractured International
Response to CRISPR-Enabled Gene Editing of Agricultural Products, 38 BIOTECHNOLOGY LAW
REPORT 3 (2019).)

genome editing as a technology with huge potential in areas including food, agriculture, and
health, but also potential risks.
The Action Plan identifies three areas of priority: (1) advancing public health by
promoting and fostering innovation in animal and plant biotechnology; (2) strengthening public
outreach and communication; and (3) increasing engagement with domestic and international
partners.
Regarding the first priority, promoting innovation in animal and plant biotechnology, the
Plan promotes a “flexible, risk-based approach . . . focusing on safety, effectiveness, and/or
regulatory questions relevant to each product for its intended use,” including, “when appropriate,
updating and clarifying science-based policies to support innovation and ensure that [FDA]
regulatory processes are efficient, predictable and proportionate to risk.”
With respect to plant biotechnology, the plan states that the FDA intends to publish draft
guidance for industry to explain FDA’s current regulatory policy for human and animal foods
produced through modern molecular plant breeding techniques. In addition, over the next two
years, the FDA intends to “begin updating the existing procedures for voluntary premarket
consultations with industry to reflect the FDA’s 25 years of experience with foods derived from
biotechnology plants and considering any additional issues related to genome editing of food
crops.”
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The EU
The regulatory requirements for genetically modified non-human organisms in the
European Union is rooted in the “GMO Directive.”45 The GMO Directive imposes substantial
regulatory obligations on member states that cover any (1) deliberate release into the
environment of a genetically modified organism (GMO) and (2) any introduction of a GMO
product on the market within the Union. The Directive requires member states to evaluate GMO
products for potential risks to the environment or human or animal health prior to release into the
environment or marketing. GMO products are also subject to traceability, labelling, and
monitoring obligations.
The GMO Directive emphasizes that the “precautionary principle has been taken into
account in the drafting of this Directive and must be taken into account when implementing it.”
As a practical matter, the Directive requires member states to impose regulatory requirements on
GMO products, such as genetically modified crops, that are quite burdensome compared to the
United States and much of the rest of the world. As a result of the more burdensome regulation,
Europe has lagged far behind the U.S. and other nations in its adoption of genetically modified
organisms in agriculture, and this has probably led to less research into agricultural
biotechnology in Europe than would have been the case under a less stringent regulatory regime.
By its terms, the GMO Directive applies to the release and marketing of any GMO,
which the Directive defines as any organism, other than a human being, in which the genetic
material has been altered in a way that does not occur naturally by mating and/or natural
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recombination. The Directive focuses on the technique used to produce the genetic modification,
and provides a nonexclusive list of specific techniques that do result in a genetic modification for
purposes of the Directive:

(1) recombinant nucleic acid techniques involving the formation of new combinations of
genetic material by the insertion of nucleic acid molecules produced by whatever means
outside an organism, into any virus, bacterial plasmid or other vector system and their
incorporation into a host organism in which they do not naturally occur but in which they
are capable of continued propagation;
(2) techniques involving the direct introduction into an organism of heritable material
prepared outside the organism including micro-injection, macro-injection and microencapsulation; and
(3) cell fusion (including protoplast fusion) or hybridization techniques where live cells
with new combinations of heritable genetic material are formed through the fusion of two
or more cells by means of methods that do not occur naturally.”46

On the other hand, the GMO Directive specifically identifies several techniques that are
not considered to result in genetic modification:

(1) in vitro fertilization;
(2) natural processes such as: conjugation, transduction, transformation; and
(3) polyploidy induction.47
46
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Finally, the Directive identifies certain techniques that are considered to result in genetic
modification of an organism, but that are specifically exempted from regulation under the
Directive:

(1) mutagenesis, and
(2) cell fusion (including protoplast fusion) of plant cells or organisms which can
exchange genetic material through traditional breeding methods.48

These exemptions are intended to encompass techniques used for genetic modification
that are not “natural,” but that predate the modern tools of biotechnology, such as recombinant
DNA technology. The justification for the exemption of these techniques is that they have a long
track record and have not been found to create any particular risks to the environment or health.
As a practical matter, the Directive has only covered the sorts of products that originally spurred
the EU’s adoption of the Directive, transgenic crops that include genetic material from another
source organism and which it would not have been feasible to create using pre-biotechnology
techniques.

The European Court of Justice Decision
In 2018, the European Court of Justice (ECJ) issued a decision (the ECJ Decision) that
addresses the important question of how the GMO Directive is to be applied to genetically
modified organisms produced using techniques that were presumably not considered when the
47
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Directive was put into effect in 2001.49 More particularly, should new methods of mutagenesis,
including mutagenesis by target-specific gene editing like CRISPR, and mutagenesis conducted
in vitro, be exempt from the Directive pursuant to the “mutagenesis exemption” described above,
or should they be subjected to the more stringent regulation applicable to the transgenic products
specifically contemplated in the Directive?
The ECJ Decision arose out of an action brought against the French Prime Minister by a
coalition of groups opposed to the use of GMOs in agriculture (the Applicants) seeking
annulment of a French law that, pursuant to the GMO Directive, exempts organisms obtained by
mutagenesis from the regulatory requirements applicable to GMOs. They also sought to compel
the French government to reverse its decision to allow the cultivation and marketing of
herbicide-tolerant rape varieties that were produced through mutagenesis, and to order the Prime
Minister to impose a moratorium on herbicide-tolerant plant varieties obtained by mutagenesis.
The Applicants argued that at the time the Directive was drafted to include a mutagenesis
exemption, the only mutagenesis techniques that were being used routinely were “conventional”
techniques performed in vivo and involving ionizing radiation or exposing plants to chemical
agents. “New mutagenesis techniques” involving in vitro random mutagenesis and directed
mutagenesis were not under consideration when the drafters of the Directive created the
exemption for mutagenesis. The Applicants argued that these new mutagenesis techniques had
made it feasible to produce GMO products that, as a practical matter, could not have been made
using conventional mutagenesis, such as ones resistant to nonspecific herbicides like glyphosate.
The Applicants argued that the use of the herbicide-resistant seeds made possible by the new
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mutagenesis techniques pose a significant risk of harm to the environment and to human and
animal health. They also expressed concern about the risk of unintentional effects, such as
undesired or off-target mutations occurring in other parts of the genome.
To this author it appears that the Applicants’ primary objection it is directed towards the
use of herbicide-resistant seeds, not the techniques used to make them per se. The problem they
have with gene editing and other new mutagenesis techniques seems to be that that these
techniques are much more powerful than conventional techniques for crop improvement, and
thus likely to result in a proliferation in Europe of herbicide-resistant crops and other forms of
crop improvement that the Applicants find objectionable.
In its July 25, 2018, decision, the ECJ held that organisms modified by means of gene
editing and other new mutagenesis techniques are GMOs for purposes of the Directive, and not
subject to the mutagenesis exemption, which was found to only be available to organisms
produced using conventional mutagenesis techniques. In arriving at its decision, the ECJ looked
towards what it perceived to be the intent of the drafters of the Directive, in particular the
specific statement in the Directive that it was drafted in consideration of the precautionary
principle, and that the precautionary principle is to be used in interpreting the Directive’s scope
and effect.
The Court found in particular that the mutagenesis exemption was based on the long
safety record of conventional mutagenesis techniques. In contrast, the Court found that the risks
to the environment or human health associated with methods of directed mutagenesis involving
the use of genetic engineering which have arisen after the GMO Directive was drafted have thus
far not been established with certainty. “[I]n essence, the risks linked to the use of those new
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techniques/methods of mutagenesis might prove to be similar to those which result from the
production and release of a GMO through transgenesis.”
The Court further found that that the direct modification of the genetic material of an
organism through mutagenesis makes it possible to obtain the same effects as the introduction of
a foreign gene into that organism, and that the development of those new techniques/methods
makes it possible to produce genetically modified varieties at a rate and in quantities quite unlike
those resulting from the application of conventional methods of random mutagenesis. “Whether
released into the environment in large or small amounts for experimental purposes or as
commercial products, [these organisms] may reproduce in the environment and cross national
frontiers, thereby affecting other Member States. The effects of such releases on the environment
may be irreversible.”
The upshot of the decision is that, so long as it remains in place, member states of the
European Union will be required to regulate products of gene editing and other new mutagenesis
techniques in the same manner as conventional GMOs. As a practical matter, this would appear
to constitute a near de facto ban on cultivating gene-edited crops in Europe, as most member
states have essentially prohibited GMOs.50 Only one genetically modified food crop, an insectresistant corn, has ever been approved in the EU.51 Cornell’s Alliance for Science aptly points
out that, “Europe now faces the bizarre situation of subjecting new plant varieties produced by
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precise gene editing to zealous and expensive regulation, while allowing hit-and-miss radiation
mutagenesis to continue to get a free pass.”52
The ECJ Decision was met with shock and dismay by proponents of biotechnology in the
European Union and abroad.53 The European Seed Association responded by declaring the ruling
“a watershed moment for the EU’s agri-food chain.” ESA Secretary General Garlich von Essen
noted: “It is now likely that much of the potential of these innovative methods will be lost for
Europe—with significant negative economic and environmental consequences. That strikes a
serious blow to European agriculture and plant science.”54 As von Essen observed, “while other
parts of the world go ahead with these innovations without unnecessary overregulation, Europe’s
breeders and farmers will once again lose out, without a chance to explore the huge potential and
benefits of these plant breeding innovations in practice.”55
In the UK, a group of scientists and industry leaders responded with an open letter to the
Secretary of State for Environment, Food, and Rural Affairs calling on the UK government to
provide clarity on the future of gene-edited crops in that country, particularly in view of Brexit
and the uncertain future relationship between the UK in the EU.56
The UK letter warns that the ECJ’s ruling has profound implications for:
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(1) UK researchers who are currently carrying out public-funded work into gene-edited
crops in research institutes and universities that is set to deliver innovative solutions to
tackle world hunger and crop adaption to climate change;
(2) UK plant breeders who will be obligated to segregate material, but will have no
means of testing material they wish to introduce into breeding lines to establish whether it
originates from an organism obtained by mutagenesis;
(3) UK farmers who are tasked with producing food sustainably at world-market prices,
under challenging and volatile circumstances, including changes in the support
framework, but do not have access to the full range of innovative tools available to other
farmers around the world;
(4) The UK agri-food industry that has already seen investment in R&D into European
agriculture by large multinational companies fall from around 33 percent of global total
30 years ago to less than 8 percent, purely as a result of an unscientific approach taken at
an EU level to the precautionary principle;
(5) UK consumers, 70 percent of whom support the use of genome editing in plants to
make crops more nutritious as a way of supplementing poor diets; and
(6) International trade, where there is a serious risk that differences in regulatory status of
gene-edited products will lead to major disruption, complicated by an inability to
distinguish between gene-edited and conventionally bred material.57

The German Bioeconomy Council, a panel of 17 researchers who advise the German
Federal Government, responded to the ECJ Decision by calling for new EU legislation governing
57
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crops created by plant-breeding technologies such as CRISPR.58 In a statement, the Council
noted, “[i]n its current form, EU genetic engineering legislation cannot do justice to the
opportunities and challenges of the technologies. We need an amendment to bring it in line with
advances in the field. It is important to have a regulation that distinguishes between mutations
and gene transfers and provides for risk-oriented approval and release procedures.” In addition to
calling for legislation that is suited to the different applications of new technologies, the Council
also argued that mandatory product labeling is not practical since modifications cannot always be
scientifically or technically detected or proven in the end product.
In its statement, the Council recommends that Germany adopt legislation “that is more
suited to the many different applications of the new technologies, from simple mutations right
through to complex genome editing, and their different risk assessments; for example, graduated
licensing and approval procedures for different classes of risk.” The Council also suggests that
“[i]n view of international trade and global supply chains, mandatory product labelling is not
sensible, since modifications cannot always be scientifically or technically detected or proven. In
order to promote consumer information and transparency, the infrastructure for voluntary
certification (e.g., ‘GMO-free’) should be strengthened.” The Council also encourages an
intensification of international exchange and collaboration in order to guarantee greater
transparency and regulatory harmonization.
On November 13, 2018, the EU Group of Chief Scientific Advisors responded to the ECJ
Decision with a document entitled A Scientific Perspective on the Regulatory Status of Products
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Derived from Gene Editing and the Implications for the GMO Directive (the “Scientific
Perspective”).59 The Scientific Perspective come to the conclusion:

in view of the [ECJ]’s ruling, it becomes evident that new scientific knowledge and
recent technical developments have made the GMO Directive no longer fit for purpose.
Moreover, the GMO Directive gives rise to more general problems, in particular with
regard to the definition of GMOs in the context of naturally occurring mutations, safety
considerations, as well as detection and identification.

The Scientific Perspective points out that when the GMO Directive was adopted in 2001,
gene editing had not yet been applied to agricultural organisms. It goes on to find that gene
editing techniques are more precise and produce fewer unintended effects than random
mutagenesis techniques, that the end product is better characterized, and that unintended effects
will occur less frequently. Consequently, the products of gene editing are potentially safer than
the products of random mutagenesis. In addition, gene editing techniques result in fewer
intermediate and unwanted varieties compared to random mutagenesis techniques.
The Scientific Perspective points out that the GMO Directive has often been interpreted
as being focused solely on production technique rather than the characteristics of the resulting
product, whereas from a scientific perspective the characteristics of the product are more relevant
than the technique used to generate them. It further points out that the Applicants’ concern about
potential environmental and safety risks of herbicide-resistant seed varieties is not addressed by
subjecting organisms produced by directed mutagenesis to the obligations of the GMO Directive
59
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because herbicide-resistant seeds could in principle be produced using random mutagenesis or
other conventional breeding methods.
The Scientific Perspective goes on to explain that it will often be impossible to detect
products of gene editing because they will be indistinguishable from mutations that have
occurred spontaneously or are the product of conventional breeding technology. The EU
Scientific Advisors report that a document is currently under preparation by the European
Network of GMO Laboratories, together with the European Commission’s Joint Research
Center, which will look in more detail at the issues related to detection, identification, and
quantification.
The Scientific Perspective observes that “meeting the obligations of the GMO Directive
implies cost- and labor-intensive pre-market evaluations and a long duration of the approval
process, which are difficult and onerous to bear, particular by small and medium enterprises,”
and that “this may diminish incentives for investment, negatively affect research and innovation
in this field, and limit the commercialization of gene edited crops.” The Scientific Advisors
specifically point to the concern that countries in the developing world exporting food and feed
to the EU might not benefit from gene-edited crops if they follow the EU authorization practice,
as some of them currently do, and that gene editing has the potential to contribute to food
security, which is particularly relevant given the growing world population and climate change.
In short, the Scientific Perspective finds a need for improving the EU’s GMO legislation
to render it “clear, evidence-based, implementable, proportionate and flexible enough to cope
with future advances in science and technology in this area.” The Scientific Advisors recommend
a revision to the existing GMO Directive to “reflect current knowledge and scientific evidence,
in particular on gene editing and established techniques of genetic modification.”
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U.S. Secretary of Agriculture Sonny Perdue responded quickly to the ECJ ruling with a
statement calling the decision a setback to scientific innovation that creates unnecessary
regulatory barriers and unjustifiably stigmatizes new technologies, by finding newer genome
editing methods to be within the scope of the European Union’s “regressive and outdated
regulations governing genetically modified organisms.” 60 His statement encourages the EU to
seek input from the scientific and agricultural communities, as well as its trading partners, in
determining the appropriate implementation of the ruling. “The global regulatory treatment of
genome-edited agricultural products has strategic innovation and trade implications for U.S.
agriculture. . . . In light of the [ECJ] ruling, USDA will re-double its efforts to work with
partners globally towards science- and risk-based regulatory approaches.”

Canada
The Canadian regulatory approach has, like that in the U.S., focused on the
characteristics of the product rather than the technique used to make the product. Canada
requires a pre-market safety assessment for agricultural biotechnology products, including
products of gene editing, only if the product expresses a new trait and could therefore pose any
risk. On the other hand, a product of gene editing that does not express a novel trait does not
require a pre-market safety assessment. In a recent presentation, the Director of the Canadian
Food Inspection Agency, Christine Tibelius, noted that since the same trait can be introduced
into a plant by any of a variety of processes, including breeding, random mutagenesis, targeted
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mutagenesis, genetic deletion, or through transgenics, it is the risk of the trait that is to be
assessed under the Canadian system, irrespective of the technique used.61

Japan
Japan has not embraced agricultural biotechnology, and there are reportedly no GMO
crops currently being grown commercially in Japan.62 According to a survey of people with food
industry experience conducted by the Environmental Ministry’s Food Safety Commission of
Japan, more than 30 percent of respondents said that even if a genetically modified crop had
been evaluated by the government for safety, they would still “feel anxious” about it.63
This has not deterred Japan from addressing the regulation of agricultural products of
gene editing. On August 20, 2018, Japan’s Ministry of Environment (MOE) held its second
technical meeting to discuss the handling of genome editing technology under the Cartagena
Protocol on Biosafety.64 The committee primarily focused on two issues: (1) the scope of
genome editing technologies which could potentially be regulated under the “Law Concerning
the Conservation and Sustainable Use of Biological Diversity through Regulations on the Use of
Living Modified Organisms” known as the Cartagena Protocol on Biosafety (the Cartagena
Protocol), and (2) the handling of technologies which would be out of scope of the Protocol (as
the result of discussion of the first issue).
61
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The committee distinguished between genome editing that adds an exogenous gene to the
genetic code of an organism, and editing that eliminates or disables sections of the organism’s
genome but inserts nothing new. Organisms produced using the former method, the committee
concluded, could impact the environment by interbreeding with preexisting species and creating
hybrids, and therefore required regulation under legislation based on the Cartagena Protocol.65
On the other hand, the committee concluded that products of genome editing technology
that do not contain “foreign nucleic acids and/or its copies” will not be categorized as genetically
engineered under the Cartagena Protocol. Similarly, the modification of the genome and the
introduction of genes which could occur naturally and/or through conventional cross breeding
will not be regulated as GE either (e.g., self-cloning and natural occurrence). 66 The committee
also judged that even organisms created by adding genes do not require regulation as long as the
alteration does not become permanent, i.e., null segregants.67

WTO statement
On October 30, 2018, a World Trade Organization (WTO) Committee issued a statement
supporting policies that facilitate agricultural innovation, including genome editing.68 As of
November 2, twelve nations had signed on to the statement, including Australia, Brazil, Canada,
Colombia, the Dominican Republic, Guatemala, Honduras, Jordan, Paraguay, the United States,
Uruguay, Vietnam, and the Secretariat of the Economic Community of West African States.69
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The primary objective of the statement is to coordinate efforts ensuring that the
regulatory approaches for agricultural products produced using precision biotechnology
techniques, including gene editing, are scientifically based and internationally harmonized, in
order to prevent regulatory asymmetries and, in turn, potential trade disruption. The signatory
nations agree that precision biotechnology techniques, as a whole, constitute an essential tool for
agricultural innovation, providing farmers with access to products that increase productivity
while preserving environmental sustainability, and recognize the important role that gene editing
and other forms of precision biotechnology could play in addressing global environmental
challenges, pest and disease pressures, food insecurity, and changes in consumer preferences.
The statement concludes that organisms produced using gene editing and other forms of
precision biotechnology may in some cases generate organisms with characteristics similar to
those obtainable through conventional breeding, while in other cases, the organisms generated
may have characteristics similar to those introduced into organisms using recombinant DNA
technologies. In either case, the statement finds that the food, animal, and environmental safety
of such products can be adequately addressed by existing regulatory frameworks for agricultural
products and existing safety standards based on the characteristics of the product or organism.
The statement warns that differing domestic regulatory approaches for products derived
from precision biotechnology may result not only in international asynchronicity in approvals,
but also in asymmetry in regulatory approaches, and may create potential trade issues that could
impede innovation. It urges governments to exercise due consideration in assessing the products
of agricultural biotechnology, in order to avoid arbitrary and unjustifiable distinctions between
end products derived from precision biotechnology and similar end products obtained through
other production methods. It also encourages government cooperation to minimize unnecessary
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barriers to trade related to the regulatory oversight of products of precision biotechnology,
including the exploration of opportunities for regulatory and policy alignment.

CONCLUSION
In short, CRISPR and other advances in gene editing are destined to bring transformative
changes to agriculture around the world. The U.S. and most other nations are embracing the
technology, and appear open to regulatory reform that focuses on the nature of the product and
reasonably foreseeable risk, while for the time being, the ECJ’s decision to subject agricultural
products of gene editing to burdensome regulation will no doubt impede its development in
Europe.
The European decision is unfortunate in many respects.70 To name one, it has been
pointed out that the decision will likely have serious implications for Africa, where CRISPR is
currently being used to develop disease-resistant varieties of important food crops such as
cassava.71 According to the European Commission, Africa is the EU’s single largest trading
partner, with Europe importing nearly $16 billion in agricultural and food products from Africa
in 2017.72 With a de facto moratorium on these products in Europe, African farmers hoping to
sell to European markets might not be able to take advantage of improvements obtainable
through gene editing. For these and other reasons, it is to be hoped that the EU takes the advice
of its own Chief Scientific Advisors and finds a way to reverse the anti-technology effect of the
Court of Justice’s decision.
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